in MagnetisMM-5 as a therapy for relapsed/refractory multiple myeloma in patients previously treated with lenalidomide and a proteasome inhibitor. Among the new phase 3 starts are CDK4 inhibitor ...

The treatment targets calpain-2, a protein believed to contribute to nerve cell damage in ALS. Participants will be randomly assigned to receive either AMX0114 or a placebo via intrathecal injection, ...

Department of Pharmaceutical Sciences, University of California, Irvine, California 92617, United States ...